Treace Medical Concepts, Inc. (TMCI)
| Previous close | 4.9400 |
| Open | 5.3300 |
| Bid | 4.8700 x 300 |
| Ask | 4.9200 x 300 |
| Day's range | 4.8600 - 5.4000 |
| 52-week range | 3.9200 - 27.7000 |
| Volume | |
| Avg. volume | 986,927 |
| Market cap | 303.22M |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Treace Medical Concepts Reports First Quarter 2024 Financial Results
PONTE VEDRA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023Gr
- GlobeNewswire
Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour
Partnership to help pickleball players of all levels with bunions and related midfoot deformities to “get back on their feet” and out on the courtDALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The Professional Pickleball Association (PPA) Tour and Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedur
- GlobeNewswire
Treace to Present at Bank of America Health Care Conference
Wednesday, May 15, 2024, at 2:20 pm Pacific TimePONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fires
